Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00737230
First received: August 15, 2008
Last updated: June 26, 2009
Last verified: June 2009

August 15, 2008
June 26, 2009
April 2007
September 2010   (final data collection date for primary outcome measure)
Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00737230 on ClinicalTrials.gov Archive Site
  • Quality of life as measured by the modified IBDQ and SF-12 questionnaires at baseline, 6 months, and 1 year [ Designated as safety issue: No ]
  • Anxiety and depression scores as measured by the Hospital Anxiety and Depression Scale questionnaire at baseline, 6 months, and 1 year [ Designated as safety issue: No ]
  • Other pelvic symptoms (i.e., urinary function as measured by the ICSmaleSF and BFLUTSQ and sexual function as measured by the IIEF-6, ICSsex, and Jensen questionnaires) at baseline, 6 months, and 1 year [ Designated as safety issue: No ]
  • Cost-effectiveness of diagnostic tests and treatment compared to "usual care" as measured by the ED-5D questionnaire at 6 months and 1 year [ Designated as safety issue: No ]
  • Cost-effectiveness of nurse practitioner delivery of algorithm compared to gastroenterologist as measured by the ED-5D questionnaire at 6 months and 1 year [ Designated as safety issue: No ]
  • Other unmet healthcare needs as a direct result of pelvic radiotherapy [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
Effective Management of Radiation-Induced Bowel Injury: A Randomized Controlled Trial

RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.

PURPOSE: This randomized clinical trial is studying the care of cancer patients with bowel injury caused by radiation therapy to the pelvis.

OBJECTIVES:

  • To undertake a systematic review of the published effectiveness of investigations and treatments for patients with radiation-induced bowel injury after pelvic radiotherapy for cancer.
  • To develop a diagnostic and treatment algorithm (based on evidence [where available] or on expert opinion [where there is no evidence]) for these patients.
  • To examine each test in the algorithm for its usefulness in establishing precise diagnoses for these patients within the context of a randomized clinical trial.
  • To examine whether use of the treatment algorithm in delivering treatment specifically targeted for each diagnosis improves symptoms and quality of life of these patients.
  • To investigate whether the same level of care can be delivered to these patients by a nurse practitioner or by a specialist consultant gastroenterologist following the same algorithm.
  • To identify other symptoms and healthcare needs experienced by these patients after pelvic radiotherapy and whether there are any other unmet needs in addition to their bowel injury.
  • To determine the cost-effectiveness of the investigations and treatments developed for these patients.

OUTLINE: This is a two-part, multicenter study.

  • Part 1: Researchers develop a diagnostic and treatment algorithm to guide health care practitioners in the management of patients with radiation-induced bowel injury. The algorithm, which is based on a systematic literature review or expert opinion, uses a series of simple tests to establish specific diagnoses and to target treatment for managing patient symptoms.
  • Part 2: Patients are stratified according to tumor site (urological vs gynecological vs gastrointestinal) and degree of bowel dysfunction as measured by IBDQ-B score > 10 points above normal [< 60 vs 60-70]). Patients are randomized to 1 of 3 intervention arms.

    • Arm I (usual care): Patients receive an advice booklet on self-management of bowel symptoms. Patients whose symptoms continue 6 months after study enrollment may cross over to arm II.
    • Arm II: Patients undergo diagnostic and treatment algorithm-led management of bowel symptoms by a gastroenterologist.
    • Arm III: Patients undergo diagnostic and treatment algorithm-led management of bowel symptoms by a nurse practitioner.

Patients complete questionnaires about bowel symptoms and other pelvic symptoms, quality of life, and anxiety and depression at baseline, 6 months, and 1 year. Patients also complete questionnaires about cost effectiveness of the diagnostic and treatment algorithm or usual care.

Interventional
Not Provided
Allocation: Randomized
Primary Purpose: Health Services Research
Cancer
  • Other: educational intervention
  • Other: questionnaire administration
  • Procedure: assessment of therapy complications
  • Procedure: gastrointestinal complications management/prevention
  • Procedure: management of therapy complications
  • Procedure: quality-of-life assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
250
Not Provided
September 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Has undergone radical pelvic radiotherapy with curative intent to the prostate, bladder, vulva, vagina, cervix, endometrium, anus, or rectum OR para-aortic irradiation for a tumor at any of these primary sites, including the testes, > 6 months ago
  • Has new-onset, troublesome gastrointestinal symptoms that developed > 6 months after completion of pelvic radiotherapy

    • Does not require immediate gastroenterological assessment, as deemed by the clinical oncologist
  • Recruited directly from radiotherapy follow-up clinics at the Royal Marsden Hospital

PATIENT CHARACTERISTICS:

  • Life expectancy > 1 year

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
Not Provided
No
Not Provided
United Kingdom
 
NCT00737230
CDR0000601214, RMNHS-CCR2918-ORBIT, EU-20868
Not Provided
Not Provided
Royal Marsden NHS Foundation Trust
Not Provided
Principal Investigator: Jervoise Andreyev, MD Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP